Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours

• Published in: European radiology 2016-03, Vol.26 (3), p.900-909
• Main Authors: Van Binnebeek, S, Vanbilloen, B, Baete, K, Terwinghe, C, Koole, M, Mottaghy, F M, Clement, P M, Mortelmans, L, Bogaerts, K, Haustermans, K, Nackaerts, K, Van Cutsem, E, Verslype, C, Verbruggen, A, Deroose, C M
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Bone Neoplasms - diagnosis; Bone Neoplasms - secondary; Female; Gallium Radioisotopes; Humans; Liver Neoplasms - diagnosis; Liver Neoplasms - secondary; Male; Middle Aged; Neuroendocrine Tumors - diagnosis; Neuroendocrine Tumors - radiotherapy; Octreotide - analogs & derivatives; Positron-Emission Tomography - methods; Radiopharmaceuticals; Somatostatin - analogs & derivatives; Tomography, Emission-Computed, Single-Photon - methods; Tomography, X-Ray Computed - methods
• ISSN: 1432-1084
• DOI: 10.1007/s00330-015-3882-1

To compare the diagnostic accuracy of (111)In-pentetreotide-scintigraphy with (68)Ga-DOTATOC-positron emission tomography (PET)/computed tomography (CT) in patients with metastatic-neuroendocrine tumour (NET) scheduled for peptide receptor radionuclide therapy (PRRT). Incremental lesions (ILs) were defined as lesions observed on only one modality. Fifty-three metastatic-NET-patients underwent (111)In-pentetreotide-scintigraphy (24 h post-injection; planar+single-photon emission CT (SPECT) abdomen) and whole-body (68)Ga-DOTATOC-PET/CT. SPECT and PET were compared in a lesion-by-lesion and organ-by-organ analysis, determining the total lesions and ILs for both modalities. Significantly more lesions were detected on (68)Ga-DOTATOC-PET/CT versus (111)In-pentetreotide-scintigraphy. More specifically, we observed 1,098 lesions on PET/CT (range: 1-105; median: 15) versus 660 on SPECT (range: 0-73, median: 9) (p